ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,572.59
0.15%
US Tech 100
19,281.60
-0.06%
Dow Jones
40,468.97
0.13%
Brent Oil
80.34
-1.44%
Bitcoin
65,957.26
-2.43%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Celyad Oncology SA (CYAD) Quote

Celyad Oncology SA

Celyad Oncology SA (CYAD)

Celyad Oncology SA
0.47
0.00
( 0.00% )
Updated: 20:00:00
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.47
Bid
0.47
Ask
0.52
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
19.472M
Previous Close
0.47
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
41,429,000
Dividend Yield
-
PE Ratio
-1.23
Earnings Per Share (EPS)
-0.2
Revenue
102k
Net Profit
-8.45M

About Celyad Oncology SA

Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm h... Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.celyad.com
Headquarters
Wavre, Walloon Brabant, Bel
Founded
1970
Celyad Oncology SA is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CYAD. The last closing price for Celyad Oncology was $0.47. Over the last year, Celyad Oncology shares have traded in a share price range of $ 0.00 to $ 0.00.

Celyad Oncology currently has 41,429,000 shares outstanding. The market capitalization of Celyad Oncology is $19.47 million. Celyad Oncology has a price to earnings ratio (PE ratio) of -1.23.

CYAD Latest News

More News

Celyad Oncology publie ses résultats financiers pour l'année 2023 ainsi que les récents évènements marquants

Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (la “Société”), annonce aujourd'hui ses résultats financiers pour l'année 2023 au 31 décembre 2023 et présente une mise...

April 04 2024
Business Wire

Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights

Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), today announces its financial results for the fiscal year 2023 ended December 31, 2023, and provides a...

April 04 2024
Business Wire

Celyad Oncology Announces Intention to Terminate SEC Reporting Obligations

Regulatory News: Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces that it will voluntarily file a Form 15F with the United States Securities and Exchange...

February 08 2024
Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

January 17 2024
Edgar (US Regulatory)

Celyad Oncology fait le point sur les activités du quatrième trimestre 2023 et présente ses perspectives pour 2024

Trois piliers principaux pour libérer le potentiel des plateformes technologiques propriétaires et de la propriété intellectuelle : Une plateforme technologique exclusive sans édition de génome...

January 16 2024
Business Wire

Celyad Oncology Provides Fourth Quarter 2023 Business Update and 2024 Outlook

Three main pillars to unlock the potential of proprietary technology platforms and intellectual property: A proprietary non-gene editing technology platform based on multiplexing of short hairpin...

January 16 2024
Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

December 21 2023
Edgar (US Regulatory)

Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC

(Article 14 §1 of the Law of 2 May 2007) Regulatory News: Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) today announces, in...

December 20 2023
Business Wire

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Regulatory News: Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces that 6,500,000 shares of CFIP CLYD (UK) Limited benefit from a double voting right as of...

December 15 2023
Business Wire

Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)

Regulatory News: Celyad Oncology SA (Euronext : CYAD) (la « Société » ou « Celyad Oncology ») annonce en ce jour que 6.500.000 actions de CFIP CLYD (UK) Limited bénéficient d’un double droit de...

December 15 2023
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
 20.10
(839.25%)
128.77k
RGCRegencell Bioscience Holdings Ltd
$ 26.54
(687.54%)
534.42k
SLRXSalarius Pharmaceuticals Inc
$ 3.325
(115.91%)
55.57M
ATPCAgape ATP Corporation
$ 0.2245
(56.99%)
97.17M
SPWRSunPower Corporation
$ 1.095
(52.98%)
156.76M
FLYEFly E Group Inc
$ 1.1199
(-82.45%)
14.96M
RNAZTransCode Therapeutics Inc
$ 0.2994
(-62.22%)
7.86M
JAGXJaguar Health Inc
$ 1.8001
(-57.84%)
13.97M
MIRAMIRA Pharmaceuticals Inc
$ 2.54
(-49.30%)
23.37M
CMAXCareMax Inc
$ 3.47
(-33.14%)
7.7M
SPWRSunPower Corporation
$ 1.095
(52.98%)
156.76M
ADILAdial Pharmaceuticals Inc
$ 1.38
(30.19%)
155.29M
SLNASelina Hospitality PLC
$ 0.025
(-32.43%)
121.47M
NVDANVIDIA Corporation
$ 122.8859
(-0.53%)
117.27M
ATPCAgape ATP Corporation
$ 0.2245
(56.99%)
97.17M

Discussion

View Full Feed
bigstocksnbonds bigstocksnbonds 4 minutes ago
Back to work ugh yes!!

My condolences!!!!
vlispxpert vlispxpert 5 minutes ago
SWIN, got more on this dip on bid ;)
SWIN
morg38off morg38off 5 minutes ago
Latest from Orie "No nothing yet which is surprising to me. They have until month end to provide response.

I’ll let you know."

My response: "Thanks, yes well this is summer and things probably come to more of a slow crawl than the usual slow crawl. :)) "
conix conix 5 minutes ago
Everything is identity politics with the Dems. Check the boxes---female, check, of color, check, accomplished biography? not needed.

At least you know that is what you do. Some people deny those check boxes.
bigstocksnbonds bigstocksnbonds 5 minutes ago
Yes awesome news!!!!!!
Rodney5 Rodney5 5 minutes ago
The terms were set Sept 7, 2008,

I would think the two gov. agencies are together on the terms on day one.

U.S. TREASURY DEPARTMENT OFFICE OF PUBLIC AFFAIRS
EMBARGOED UNTIL 11 a.m. (EDT), September 7, 2008
CONTACT Brookly McLaughlin, (202) 622-2920
FNMA
dstock07734 dstock07734 5 minutes ago
The past journey is full of trials and tribulations. But the journey ahead will be an exciting one.

Can you believe all what three BPs can do is introducing a small tweak on the injection mode? What kind of benefit can cancer patients get from the little tweak? The only benefit is as
NWBO
JoseSD JoseSD 5 minutes ago
hahahahahaahahha GO HYPER HYPER! I miss you guys...
HYSR
100lbStriper 100lbStriper 5 minutes ago
NLST BABY !!! GET SOME !!!
NLST
scortech scortech 6 minutes ago
Taken from their own press release
CGAC
hopester hopester 6 minutes ago
They're burning cash at a rate that cannot be sustained. If they had something to show for it it would be one thing. But $25mil cash burnmore or less per quarter, combined with ongoing losses and only promises to live by produces the sh/px investors are suffering with.
The company is forced i
FCEL
Monksdream Monksdream 6 minutes ago
GWAV new 52 week low
https://investorshub.advfn.com/uimage/uploads/2024/7/23/gzyrhIMG_9918.gif
GWAV
TradingCharts TradingCharts 6 minutes ago
Massless Energy Storage – Structural battery with record performance
[yt]IB81lkPGGlE[/yt]
JoseSD JoseSD 6 minutes ago
another partnership!!! WOOOOHOOOOOOOO how many they have already? 10? 20?
HYSR
dukeb dukeb 6 minutes ago
Well, TFG likes the song because he wants his unwashed minions to stay there. Those hooples certainly aren't getting past the doorman at any Trump property, that's for sure.

Why do Republicans like it so much?
Mr.Fields Mr.Fields 7 minutes ago
More trading activity and a strong rise in price are expected to fill a gap that's clearly visible on the chart. If we go above $7, some doubters and market influencers might try to prevent further gains.
AVXL
vlispxpert vlispxpert 7 minutes ago
SWIN thanks for more shares ;)
SWIN
Acme Investments Acme Investments 7 minutes ago
Alright Chartmiester a realistic prediction!! I might start loading at .0035!!
NSAV
docsetc docsetc 7 minutes ago
I'd lay down a bet Kelli doesn't pay by the 45-day deadline and a bench warrant will be issued for nonpayment. Hope Kostiner gets worse, Harry too. Let ENZC be the albatross that sinks them so far under, they can all wave "hi" to Leo DeCaprio in the belly of the Titanic.

In any class
ENZC
gosox12 gosox12 8 minutes ago
If you read some recent posts, there have been lots of promising company developments. Getting the CE removed by the OTC still looks to me like a LOTTERY PICK!!! Going on almost 2 years since it was first placed by the OTC. Until it's removed, we're screwed.

I'll stick around till De
CYBL
Monksdream Monksdream 8 minutes ago
WWW new 52 week high
https://investorshub.advfn.com/uimage/uploads/2024/7/23/qfpewIMG_9917.gif
WWW
Lime Time Lime Time 8 minutes ago
Bidder moved up to .0027

Gonna be a great 2025 🚀
GVSI
dloggold dloggold 8 minutes ago
you saw that number on this site of all places for a day .
that is hardly evidence of anything
Mojocash Mojocash 9 minutes ago
Yeah yeah! I read the case years ago. The address was ficticious and the case tossed. It was all propaganda. The left has no bounds. It was indeed debunked and a fake case. There was even a fake picture of the girl "Katie Johnson".
peanutz peanutz 9 minutes ago
15 cents to 45 cents in a hurry . Back down to 24
ATPC

Your Recent History

NASDAQ
CYAD
Celyad Oncology
EU
ALMAR
Mare Nostrum
BOV
INTB3F
Intelbras S.A ON
BOV
GSFI11
General Shopping E Outle...
BOV
RAPT4
RANDON PART PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved